Pulse Biosciences Partners With Clayman Thyroid Center for nPulse Vybrance Deployment

Key highlights

• Clayman Thyroid Center becomes the exclusive Tampa Bay site offering nPulse technology for thyroid nodules
• Commercial agreement enables immediate use of the Vybrance System under a controlled market strategy
• Clinical collaboration will focus on generating outcomes data and conducting formal studies on nsPFA utility
• The partnership leverages the high-volume referral patterns of one of the nation's largest thyroid centers
• Clinical data collection aims to reinforce the safety profile of non-thermal energy near critical structures

What Is the Partnership?

Pulse Biosciences has formalized a dual-track partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery. The agreement encompasses both the immediate commercial deployment of the nPulse Vybrance Percutaneous Electrode System and a strategic clinical alliance. Under the commercial terms, the Tampa-based center has commenced treating patients with symptomatic benign thyroid nodules using the proprietary nanosecond Pulsed Field Ablation technology. This marks a key step in the company’s controlled market development strategy, positioning the Clayman Thyroid Center as the exclusive provider of nPulse technology within the Tampa Bay region.

Partner Profile

• The Clayman Thyroid Center operates within the Hospital for Endocrine Surgery in Tampa, Florida
• Recognized as one of the largest specialized thyroid surgery centers in the United States
• Maintains significant regional and national patient referral patterns for endocrine disorders
• Specializes in minimally invasive treatments for benign and malignant thyroid conditions
• High-volume throughput provides a platform for large-scale clinical data collection

What It Unlocks

The partnership serves as a conduit for Pulse Biosciences to validate its nsPFA technology in a high-volume clinical setting. By collaborating on the collection of real-world outcomes, the company aims to build a robust body of evidence to support broader market adoption. The non-thermal nature of the Vybrance System allows for the clearing of ablated cells while preserving critical adjacent structures like nerves and blood vessels. This tie-up complements the company’s ongoing research with MD Anderson Cancer Center, expanding its clinical footprint in both benign and malignant thyroid applications.

Financial Context

• Pulse Biosciences reported quarterly revenue of $0.434 million as of the latest reporting period
• No backlog or order book was reported as of June 30, 2026, in SEC filings
• Management reiterated plans to file for a European CE Mark for the nPulse Cardiac Surgical System by end of 2026
• Third-quarter 2026 financial results are estimated to be released on November 4, 2026
• Potential CE Mark approval for the cardiac system is targeted for mid-2027

Down 10.5% over the last month ($54.21 on 14 Sep → $48.54 on 13 Oct). Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$54.21
15 Sep	$55.20
16 Sep	$49.61
17 Sep	$50.61
18 Sep	$53.87
21 Sep	$53.31
22 Sep	$52.69
23 Sep	$51.98
24 Sep	$51.83
25 Sep	$51.63
28 Sep	$52.32
29 Sep	$50.89
30 Sep	$49.92
1 Oct	$49.83
2 Oct	$47.90
5 Oct	$50.50
6 Oct	$49.75
7 Oct	$49.09
8 Oct	$49.98
9 Oct	$53.81
12 Oct	$52.45
13 Oct	$48.54

Management commentary

“The Clayman Thyroid Center is one of the largest thyroid surgery centers across the country with significant regional and national referral patterns.”

PULSE BIOSCIENCES, INC. · financial snapshot

Share price	$48.54
Market cap	$3.5B
Revenue (annual)	$350,000
1-month price change	-8.60%
Sector	HealthcareMedical Instruments & Supplies

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.